- Home
- NMRA
NMRA
Neumora Therapeutics Inc.
as 11-15-2024 4:00pm EST
Stocks
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | N/A | IPO Year: | 2023 |
| Target Price: | $23.40 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.33 - $21.00 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Neumora Therapeutics Inc. (NMRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Fust Matthew K | NMRA | Director | Oct 17 '24 | Sell | $17.02 | 21,788 | $370,961.81 | 20,100 | |
| Lenz Robert A. | NMRA | Head of R&D | Oct 9 '24 | Sell | $15.05 | 13,823 | $208,110.23 | 314,706 | |
| Lenz Robert A. | NMRA | Head of R&D | Sep 17 '24 | Sell | $11.95 | 41,464 | $492,826.58 | 314,706 | |
| Lenz Robert A. | NMRA | Head of R&D | Sep 12 '24 | Sell | $11.43 | 32,948 | $376,664.83 | 314,706 | |
| Pinto Joshua | NMRA | Chief Financial Officer | Aug 27 '24 | Sell | $11.39 | 15,693 | $178,806.04 | 138,965 | |
| Pinto Joshua | NMRA | Chief Financial Officer | Aug 22 '24 | Sell | $11.66 | 84,307 | $984,061.15 | 138,965 |
Latest Neumora Therapeutics Inc. News
NMRA Breaking Stock News: Dive into NMRA Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Neumora Therapeutics Q3 Loss Narrows
GlobeNewswire
5 days ago
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
11 days ago
Neumora Therapeutics to Participate in Upcoming Conferences in November
MT Newswires
12 days ago
JPMorgan Downgrades Neumora Therapeutics to Neutral, $15 Price Target
GlobeNewswire
19 days ago
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
MT Newswires
a month ago
Neumora Therapeutics Insider Sold Shares Worth $370,962, According to a Recent SEC Filing
Simply Wall St.
2 months ago
Neumora Therapeutics (NASDAQ:NMRA) Is In A Good Position To Deliver On Growth Plans
GlobeNewswire
3 months ago
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
Compare NMRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NMRA Neumora Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.